Payment changes of authority’s fees in France

pharmafile | January 20, 2012 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wainwright Associates, regulatory affairs 

Changes are being made in the way fees are paid for regulatory submissions and procedures in France.  Fees are no longer payable to the French regulatory authority, but will become payable to the State.  Implementation of the arrangements is expected shortly and in the meantime transitional arrangements apply.  National fee rules for Marketing Authorisation Applications (MAAs) and other regulatory procedures can be complex with different authorities having their own national sets of rules to interpret; as with France, these rules may also change from time to time and fee reviews take place at different times of the year in different countries.  Expert advice helps avoid inadvertent overpayments, and also underpayments which may delay validation and procedure start dates.

With its network of local regulatory advisors, Wainwright Associates is pleased to advise on and organise fee payments in nearly 65 countries on behalf of its clients.  If we can help, please contacts us on +44 (0)1628 530554 or email enquiries@wainwrightassociates.co.uk.

 

Related Content

Europe vs USA: New drug approvals

Dr Terese Johansson, Regulatory Affairs Consultant NDA Group AB, examines the drop in US approvals …

EMA backs full access to trial data

The European Medicines Agency says it wants to open up access to full clinical trial …

Submission of labels and leaflets in the UK

The MHRA has announced procedural changes concerning the requirement to submit full-colour mock-ups of labels …

Latest content